Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université Pierre Et Marie Curie (paris 6)

Sorbonne Université

Essilor International

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Assistance Publique-hopitaux De Paris

Universitéde Strasbourg

Université Paris—sud

Friedrich Miescher Institute for Biomedical Research

Chambre De Commerce Et D'industrie De Region Paris Ile De France (esiee Paris)

Université Pierre Et Marie Curie

Chambre De Commerce Et D'industrie De Region Paris Ile De France

Inserm

Serge Picaud

Jose-Alain Sahel

Ryad Benosman

Coralie Barrau

Guillaume Chenegros

Lionel Rousseau

Siohoi Ieng

Botond Roska

Dominique Conte

Thierry Villette

Marc J Ledoux

Florian Sennlaub

Nicolas Keller

Pierre Bernhardt

Christophe Plessis

Philippe Bergonzo

Nicolas Libert

Gaelle Lissorgues

Deniz Dalkara

Camille Ehrismann

Henri Lorach

Blaise Yvert

Jens Duebel

Valérie Keller-Spitzer

Amel Bendali

Romain Bernard

Valèrie Keller-Spitzer

Michel Roux

Myline Cottance

Anne Robe

Julie Degardin

Shankar Muthukonda Venkatakrishnan

Thomas Cottineau

Denis Cohen-Tannoudji

Milan Djilas

Emilie Arnault

Bénédicte Dupas

Alain Gaudric

Alvaro Rendon

Abdoulaye Sene

Ramin Tadayoni

Eric Vicaut

Mélanie Marie

Valerie Forster-Fradot

Valérie Fradot

Jacques Durenteau

José-Alain Sahel

Alexis Bemelmans

Melissa Desrosiers

Anatole Harrois

Jammoul Firas

Caroline Coriat

Gaëlle Lissorgues

Manuel Simonutti

Thierry Pierre Villette

Ryad Benjamin Benosman

José Sahel

Valérie Foster-Fradot

The invention relates to filter dedicated to protect eye cone cells and method associated. The eye cone cells protecting filter is intended to be applied to a transparent surface and to filter incident light for preventing eye cone cells of a user, from damages due to illumination at physiological light levels on the eye of said user, and having spectral characteristics to i) filter light wavelengths between 405 and 465 nanometers, and ii) transmit a filtered light reaching the eye cone cells and having a harmfulness on said eye cone cells under a predefined maximum threshold.

Filter for eye cone cells protection

The present invention relates to a nucleic acid sequence derived from the regulatory region of the human gamma-synuclein gene and having a promoter activity in retinal ganglion cells. The present invention also relates to expression cassettes or vectors comprising said promoter operably linked to a nucleic acid sequence encoding a polypeptide of interest as well as viral particles or host cells comprising said expression cassette or vector. The present invention also relates to the use of said expression cassettes, vectors, viral particles or cells in the treatment of ocular disease, in particular ocular disease associated with retinal ganglion cell or photoreceptor cell degeneration.

Promoters and uses thereof

Disclosed is an imaging device including a light source arranged so as to generate an optical signal, an optical support coupled to the light source and arranged so as to project a luminous excitation signal with a substantially constant light intensity, from the light source to a body to be observed during the use of the device, and an asynchronous camera coupled to the optical support and designed so as to generate a signal including, for each pixel of a first pixel matrix, a signal sequence representing asynchronous events corresponding to variations of the light backscattered by the body to be observed for the pixel.

Imaging device and method

The invention relates to a process for manufacturing at least one implant for focal electrical stimulation of a nervous structure, said implant being of the type including in a supporting structure a network of cavities at the bottom of which are placed microelectrodes, the cavities being bounded by walls erected and located around the microelectrodes, the supporting structure being produced beforehand by implementing the following steps: deposition and etching, in a planar manner, on an insulating substrate, of electrical contacts, of electrical tracks and of microelectrodes, first tracks electrically connecting the microelectrodes and the electrical contacts, second electrical tracks being electrically connected to a ground.

Process for manufacturing an implant for focal electrical stimulation of a nervous structure

A device for displaying an image sequence in the form of a pixel matrix, includes a control unit coupled to a projector. The control unit includes an input interface designed to receive asynchronous information representing, for each pixel of the matrix, events concerning the pixel, and a processor designed to control the activation of each pixel of the matrix at moments determined by the respective events indicated by the asynchronous information for the pixel. The projector is disposed on a support so as to illuminate the light receptors of the eye when the device is in use and is designed to project a light flux corresponding to the pixels activated by the control unit.

Device for displaying an image sequence and system for displaying a scene

Method of determining configuration of interferential filtering elements for an optical device having an optical substrate for a user, includes:

Method of determining the configuration of an ophthalmic filter

A biocompatible carbon based electrode, and its preparation process are described. The electrode is formed by first and second biocompatible chemically oxygen terminated or H-terminated carbon-based materials. The first material is configured to promote the growth or at least the direct interfacing of adult neurons on the first material without substantially promoting the growth and direct interfacing of glial cells on the first material. The second material presents a peptide coating to promote the growth and at least the direct interfacing of adult glial cells.

Biocompatible carbon based electrode and its preparation process

The use of substance selected from taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation, and a pharmaceutical composition including the substance and the active ingredient.

Anticonvulsive pharmaceutical compositions

An artificial retina that includes: (i) a substrate; (ii) a first layer, placed onto said substrate and including photovoltaic material portions separated by at least one insulating material portion; and (iii) a second layer, placed onto said first layer and including conductive material portions separated by at least one insulating material portion. In said artificial retina, the photovoltaic material includes a titanium dioxide semiconductor.

Artificial retina that includes a photovoltaic material layer including a titanium dioxide semiconductor

The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate (), a array of recesses () formed in an upper surface of the substrate, stimulation electrodes () arranged at the bottom of the recesses, and an electrically conductive layer forming a ground plane () at the upper portion of the recesses. The sizes of the recesses and of the electrodes of the implant are such that the spatial selectivity of the stimulation current applied to the nerve structure is maximized.

Implant having three-dimensional shape for electrically stimulating a nerve structure

The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.

Methods for modulating angiogenesis via dystrophin Dp71

Growing community of inventors

Avon, France

Serge Picaud